用基因芯片筛选高转移卵巢癌细胞系转移相关基因

用标准化的Affymetrix公司生产U133A基因芯片技术研究高(H)转移卵巢癌细胞株(HO-8910PM)和正常卵巢上皮(C)基因表达谱差异,筛选与卵巢癌转移相关的基因及其在染色体的定位和功能。结果发现高转移卵巢癌细胞株和正常卵巢上皮比较表达差异8倍以上共有1,237个基因,其中表达上调(信号比的对数值SLR≥3)有597个,表达下调(SLR≤-3)有640个。从表达差异的基因在染色体定位分析,发现除1个基因未知其定位外,其余所有差异表达基因散在分布在各条染色体上,但以1号染色体最多,有115个(9.3%)。其次是2号染色体有94个(7.6%),第三是12号染色体有88个(7.1%)。第四是11号染色体有76个(6.1%)。第五是X染色体有71个(5.7%)。第6是17号染色体有69个(5.6%)。而差异表达的基因发生在染色体短臂(q)上有805个(占65.1%),在13,14,15,21和22号仅发现在q上有差异表达基因。从表达差异的基因分子功能分类看,属于酶和酶调控子基因最多(306个,占24.7%),其次是核酸结合基因(144个,占11.6%)。第三类是信号传导基因(137个,占11.1%)。第四类是蛋白结合基因(116个,占9.4%)。以上4大类共占基因总数56.8%。还有功能未知的基因有207个,占16.7%。结论:高转移卵巢癌细胞株差异表达基因散在分布在各条染色体上,但以1、2、12、11、17和X染色体差异表达基因居多,肿瘤的转移是多基因共同作用的结果。4大类(酶和酶调控子活性、核酸结合活性、信号传导活性、蛋白结合活性)差异表达基因是我们今后研究卵巢癌转移相关的重要基因。     

胃癌差异表达基因在染色体上的定位及其功能分析

利用标准化的Affymetrix公司生产的U133A基因芯片检测胃癌（T）与切缘正常胃黏膜（C）基因表达谱差异,并利用生物信息学方法对检测结果进行差异基因在染色体定位和功能分析。结果表明：胃癌与正常胃黏膜比较差异8倍以上共有270个基因,其中表达上调[信号比的对数值（SLR）≥3]有157个,表达下调（SLR≤-3）有113个。从表达差异的基因在染色体定位分析,发现除4个基因未知其定位外,其余所有差异表达基因散在分布和各条染色体上,但以1号染色体为最多,有26个（占9．8％）,其次是11和19号染色体上分别有24个（各占9．1％）。而差异表达的基因发生在染色体短臂（q）上有173个（占65％）。从表达差异的基因功能分类看,属于酶和酶调控子基因最多（67个,24．8占％）,其次是信号传导基因（43个,占15．9％）,第3类是核酸结合基因（17个,占6．3％）,第4类是转运子基因（15个,占5．5％）,第5类是蛋白结合基因（12个,占4．4％）,还有功能未知的基因有50个,占18．5％。以上5大类共占基因总数56．9％。胃癌差异表达基因散在分布在各条染色体上,但以1、11、19号染色体差异表达基因居多。这5大类（酶和酶调控子、信号传导、核酸结合、转运子、蛋白结合）相关基因异常是今后研究胃癌的重要基因。     

转录因子FOXM1在卵巢癌细胞中的表达及其对侵袭转移能力的影响

目的:研究上皮性卵巢癌细胞中FOXM1的表达,探讨FOXM1与MMP9之间的相关性以及与卵巢癌细胞侵袭、转移的关系。方法:采用Real-time RT-PCR、Western blotting技术检测pcDNA3.1-FOXM1和FOXM1-siRNA分别转染卵巢癌细胞株HO-8910(低转移)和HO-8910PM(高转移)前后FOXM1的表达水平,用Transwell方法检测转染该序列后HO-8910和HO-8910PM细胞侵袭能力的改变,并用荧光素酶双报告基因分析技术检测FOXM1对MMP9的调控作用。结果:与对照组和空载组相比,转染了pcDNA3.1-FOXM1的HO-8910细胞FOXM1 mRNA、蛋白表达显著升高,而转染了FOXM1-siRNA的高转移细胞株HO-8910PM FOXM1 mRNA、蛋白表达显著降低(P0.05);相对于空载体组和空白组,pcDNA3.1-FOXM1转染组细胞的侵袭能力明显增强,而FOXM1-siRNA转染细胞的侵袭能力明显降低(P0.05);FOXM1参与对MMP9的转录调控作用(P0.05)。结论:FOXM1可能是一个潜在的治疗靶点,通过下调FOXM1的表达,从而抑制卵巢癌的浸袭和转移。     

Notchl信号蛋白在卵巢癌细胞系中的表达

目的：检测卵巢癌细胞系中Notchl信号蛋白的表达,为在卵巢癌细胞中对Notchl进行RNA干涉研究的体外实验筛选靶细胞。方法：采用逆转录聚合酶链反应（RT-PCR）法及Westernblotting对卵巢癌细胞系SKOV3、HO-8910、HO-8910-PM和3AO中Notchl进行检测。结果：Notchl信号蛋白在4种卵巢癌细胞系中均有表达,其在HO-8910-PM中表现为高表达,在SKOV3和3AO中表现为中等表达,在HO-8910中表现为低表达。结论：HO-8910-PM适合作为靶细胞,进行Notchl信号蛋白的RNA干涉研究。     

TaqmanqPCR检测CD147／Basigin剪接变异体在人上皮性卵巢癌中的表达

目的：应用TaqmanqPCR技术检测CDl47／basigin剪接变异体在人上皮性卵巢癌组织与正常卵巢组织中的表达差异。方法：运用半定量RT．PCR技术检测CDl47／basigin剪接变异体在上皮性卵巢癌细胞系中的表达;TaqmanqPCR检测CDl47／basigin剪接变异体在人上皮性卵巢癌细胞系中的表达分布;进一步通过收集32例上皮性卵巢癌组织与26例正常卵巢组织,提取组织RNA,反转录cDNA,TaqmanqPCR检测CDl47／basigin剪接变异体mRNA在上皮性卵巢癌组织与正常卵巢组织中的表达差异。结果：半定量RT-PCR结果显示basigin-2,basigin-3和basigin-4在上皮性卵巢癌细胞系中均有表达,主要以basigin-2为主;TaqmanqPCR检测到三种剪接变异体在不同卵巢癌细胞系中表达不同,basigin-2在卵巢癌细胞系中较basigin一3,basigin-4表达较高,basigin一4较basigin．3略高;Basigin．2剪接变异体在高转移Ho．8910pm细胞中表达较高,在低转移HO一8910细胞中表达较低。组织TaqmanqPCR检测basigin-2和basigin-4在上皮性卵巢癌组织中的表达水平显著高于正常卵巢组织（P值分别为〈0．0001和0．0261）,basigin．3的表达水平略有升高（P=0．2616）,但无统计学意义。结论：三种剪接变异体在卵巢癌组织中较正常卵巢组织表达上调。CDl47／basigin．2在高转移卵巢癌细胞系HO-8910pm中高表达,在低转移卵巢癌细胞系HO-8910中低表达,且表达强度与上皮性卵巢癌的转移相关;探讨CDl47／basigin一2在上皮性卵巢癌中的高表达,为卵巢癌的进一步治疗开辟一新途径。     

EGCG经AKT1-Mdm-2-p53途径抑制卵巢癌HO-8910细胞的增殖

目的：初步探讨EGCG对卵巢癌HO-8910细胞增殖的抑制作用及其机制。方法：通过绘制细胞生长曲线、平皿克隆和软琼脂集落形成实验观察EGCG对HO-8910细胞增殖的抑制作用;Westem—blotting检测AKT1、Mdm-2与p53蛋白的表达。结果：（1）细胞生长曲线、平皿克隆和软琼脂集落形成实验结果显示,EGCG可有效抑制HO-8910细胞的增殖（n=3,P〈0．05）。（2）Western—blotting检测结果显示,EGCG处理后AKT1与Mdm-2蛋白表达均降低,而p53蛋白表达升高（P〈0．05）。结论：EGCG通过抑制HO-8910细胞中AKT1与Mdm-2蛋白表达,促使p53蛋白表达而发挥其对细胞增殖的抑制作用。     

Notch1信号蛋白在卵巢癌细胞系中的表达

目的:检测卵巢癌细胞系中Notch1信号蛋白的表达,为在卵巢癌细胞中对Notchl进行RNA干涉研究的体外实验筛选靶细胞.方法:采用逆转录聚合酶链反应(RT-PCR)法及Western blotting对卵巢癌细胞系SKOV3、HO-8910、HO-8910-PM和3AO中Notch1进行检测.结果:Notch1信号蛋白在4种卵巢癌细胞系中均有表达,其在HO-8910-PM中表现为高表达,在SKOV3和3AO中表现为中等表达,在HO-8910中表现为低表达.结论:HO-8910-PM适合作为靶细胞,进行Notch1信号蛋白的RNA干涉研究.     

卵巢上皮癌细胞株间APE1单核苷酸多态性的研究

目的:检测APE1单核苷酸多态性变化在卵巢上皮癌细胞株HO-8910、A2780、SKOV3间的表达,对进行大样本临床病例对照研究探讨APE1遗传变异与卵巢癌易感性关系进行指导.方法:提取各细胞株基因组DNA,PCR扩增目的片段,直接测序法检测产物APE1位点rs1760944、rs1130409和rs2307486在细胞株中的基因表达,测序结果解读采用Chromas2软件,并结合NCBI及HapMap数据库分析测序结果.结果:测序结果发现rs1130409突变型等位基因(G)位于细胞株A2780中,基因型为T/G;其野生型等位基因(T)位于HO-8910及SKOV3,基因型均为T/T; rs 1760944突变型等位基因(G)位于细胞株A2780、SKOV3及HO-8910中,基因型均为G/G;rs2307486在三株细胞株均为野生型纯合子A/A.结论:APE1基因位点rs 1130409与rs 1760944在卵巢癌上皮细胞株HO-8910、A2780、SKOV3间存在单核苷酸多态性变化,提示其单核苷酸多态性可能与卵巢上皮癌易感性相关;rs2307486在HO-8910、A2780、SKOV3中不存在多态性改变,提示其单核苷酸多态性与卵巢上皮癌易感性可能无关.     

Smad4基因在人卵巢癌高、低转移细胞系HO-8910和HO-8910PM中的表达及其对肿瘤转移作用的研究

转化生长因子β（transforming growth factor,TGF-β）超家族广泛存在于多种生物的各种组织中,参与细胞增殖分化、血管形成、肿瘤发生、细胞外基质形成等多种生物学事件。Smad4是TGF-t3／Smads信号通路中的关键分子,研究表明,Smad4的过表达可以抑制肿瘤细胞的增殖和细胞外基质的合成并诱导凋亡。本实验利用人高低转移性卵巢癌细胞系HO-8910PM和HO-8910细胞系作为对象通过基因转染技术过表达Smad4,     

FAP-alpaha在胞外信号传递中与整合素的关系

目的：研究成纤维激活蛋白（Fibroblast Activation Protein,FAP）在促进卵巢癌细胞发生侵袭、迁移、增殖过程中与整合素α3β1、尿激酶型纤溶酶原激活剂受体（uPAR）的关系。方法：1）．免疫共沉淀共同检测整合素α3β1、uPAR在HO-8910PM上是否为二聚体。2）．transwell侵袭实验、迁移实验检测抑制整合素α3β1、uPAR后,卵巢癌细胞系HO-8910PM的侵袭迁移能力;3）．抑制整合素α3β1、uPAR后,再给予FAPet对HO-8910PM侵袭、迁移和增殖的影响。结果：1）．整合素α3β1、uPAR在HO-8910PM细胞外同一个位置表达;2）．抑制整合素α3β1能够明显抑制HO-8910PM的侵袭、迁移、增殖能力,并且可以抑制FAP对肿瘤的作用。3）．PAI—1抑制uPAR后,HO—8910PM的侵袭、迁移、增殖无明显变化,同时对FAP也无明显作用。结论：整合素α3β1和uPAR在HO-8910PM是一个复合体,FAPα,在细胞外是通过整合素α3β1传递信号进入细胞内而不是通过uPAR,整合素α3β1是通过uPAR与肿瘤细胞相连接。     

Identification of Differentially Expressed Genes in the High and Low Metastatic Human Ovarian Cancer Cell Lines and Analyses of Their Chromosomal Localizations and Functions

Oligonucleotide microarrays were used to study the differences of gene expressions in high (H) and low (L) metastatic ovarian cancer cell lines and in normal ovarian tissues (C). Bioinformatics was used to identify novel genes and their functions as well as chromosomal localizations. A total of 409 genes were differentially expressed between the high and low metastatic ovarian cancer cell lines. Of them, 271 genes were up regulated (Signal Log Ratio[SLR] ≥1), and 138 genes were down regulated (SLR≤-1). Except one gene whose location was unknown, all these genes were localized randomly on all the chromosomes, with a majority of them localized to Chromosomes 1, 6, 2, 17, 3, 5 and 11. Chromosome 1 contained, 43 of them (10.7%), the most for a single chromosome. A total of 264 genes (64.7%) were localized on the short arm of the chromosome (q). Functional classification showed that the 104 (25.4%) genes coding for enzymes and enzyme regulators made up the largest functional group, followed by signal transduction activity genes (43, 10.5%), nucleic acid binding activity genes (42, 10.3%), and proteins binding activity genes (34, 8.3%). These four groups accounted for 54.5% of all the differentially expressed genes. In addition, the functions of 76 genes (18.6%) were unknown. Tumor metastasis is the result of a number of genes acting in concert. The four functional groups of genes classified among these genes and their abnormalities would be the focus of further studies on ovarian cancer metastasis.     

Function and Chromosome Location of Differentially Expressed Genes in Gastric Cancer

Using Affymetrix U133A oligonucleotide microarrays, screening was done for genes that were differentially expressed in gastric cancer (T) and normal gastric mucosa (C), and their chromosome location was characterized by bioinformatics. A total of 270 genes were found to have a difference in expression levels of more than eight times. Of them 157 were up-regulated (Signal Log Ratio [SLR]≥3), and 113 were down-regulated (SLR≤-3). Except for, four genes with unknown localization, a vast majority of the genes were sporadically distributed over every chromosome. However, chromosome 1 contained the most differentially expressed genes (26 genes, or 9.8%), followed by chromosomes 11 and 19 (both 24 genes, or 9.1%). These genes were also more likely to be on the short-arm of the chromosome (q), which had 173 (65%). When these genes were classified according to their functions, it was found that most (67 genes, 24.8%) belonged to the enzymes and their regulators groups. The next group was the signal transduction genes group (43 genes, 15.9%). The rest of the top three groups were nucleic acid binding genes (17, 6.3%), transporter genes (15, 5.5%), and protein binding genes (12, 4.4%). These made up 56.9% of all the differentially expressed genes. There were also 50 genes of unknown function (18.5%). Therefore it was concluded that differentially expressed genes in gastric cancer seemed to be sporadically distributed across the genome, but most were found on chromosomes 1, 11 and 19. The five groups associated genes abnormality were important genes for further study on gastric cancer.     

杨盘二孢菌诱导的杨树差异表达基因的功能分析和染色体定位

利用cDNA芯片技术从含有2,952个克隆的杨树芯片中筛选出1,160个受杨盘二孢菌诱导的基因。功能分析表明,该1,160个基因分别属于11个功能类别,除了功能未知基因外,参与新陈代谢、防御反应、信号传导及转录调控的基因最多,这4大类基因约占基因总数的42%。1,160个差异表达基因中有926个基因被定位于19条染色体上,其中被定位于第Ⅱ条染色体上的差异基因最多,共102个(11.0%),其次是第Ⅰ条染色体,共93个(10%),被定位到第ⅩⅦ条染色体上的差异基因最少,仅有11个,基因在染色体上的分布则表现为在部分染色体的末端区域存在大量的聚集,在中间区段则相对较少和排列稀疏,基因的这种分布情况与植物抗病的关系有待进一步研究。     

Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1

The breast cancer metastasis suppressor 1 (BRMS1) gene has been shown to suppress metastasis without affecting the growth of the primary tumor in mouse models. It has also been shown to suppress the metastasis of tumors derived from breast, melanoma, and, more recently, ovarian carcinoma (see ref 1). However, how BRMS1 exerts its metastasis suppressor function remains unknown. To shed light into its metastatic mechanism of action, the sensitive 2D-DIGE analysis coupled with MS has been used to identify proteins differentially expressed by either overexpressing (Mel-BRMS1) or silencing BRMS1 (sh635) in a melanoma cell line. After comparison of the protein profiles from WT, Mel-BRMS1, and sh635 cells, 79 spots were found to be differentially expressed. Mass spectrometry analysis allowed the unambiguous identification of 55 polypeptides, corresponding to 43 different proteins. Interestingly, more than 75% of the identified proteins were down-regulated in Mel-BRMS1 cells compared to WT. In contrast, all the identified proteins in sh635 cells extracts were up-regulated compared to WT. Most of the deregulated proteins are involved in cell growth/maintenance and signal transduction among other cell processes. Six differentially expressed proteins (Hsp27, Alpha1 protease inhibitor, Cofilin1, Cathepsin D, Bone morphogenetic protein receptor2, and Annexin2) were confirmed by immunoblot and functional assays. Excellent correlation was found between DIGE analysis and immunoblot results, indicating the reliability of the analysis. Available evidence on the reported functions of the identified proteins supports the emerging role of BRMS1 as negative regulator of the metastasis development. This work opens an avenue for the molecular mechanisms' characterization of metastasis suppressor genes with the aim to understand their roles.     

Combining bioinformatics techniques to explore the molecular mechanisms involved in pancreatic cancer metastasis and prognosis

This article aims to explore the underlying molecular mechanisms and prognosis‐related genes in pancreatic cancer metastasis. Pancreatic cancer metastasis‐related gene chip data were downloaded from GENE EXPRESSION OMNIBUS(GEO)database. Differentially expressed genes were screened after R‐package pre‐treatment. Functional annotations and related signalling pathways were analysed using DAVID software. GEPIA (Gene Expression Profiling Interactive Analysis) was used to perform prognostic analysis, and differential genes associated with prognosis were screened and validated using data from GEO. We screened 40 healthy patients, 40 primary pancreatic cancer and 40 metastatic pancreatic cancer patients, collected serum, designed primers and used qPCR to test the expression of prognosis‐related genes in each group. 109 differentially expressed genes related with pancreatic cancer metastasis were screened, of which 49 were up‐regulated and 60 were down‐regulated. Functional annotation and pathway analysis revealed differentially expressed genes were mainly concentrated in protein activation cascade, extracellular matrix construction, decomposition, etc In the biological process, it is mainly involved in signalling pathways such as PPAR, PI3K‐Akt and ECM receptor interaction. Prognostic analysis showed the expression levels of four genes were significantly correlated with the overall survival time of patients with pancreatic cancer, namely SCG5, CRYBA2, CPE and CHGB. qPCR experiments showed the expression of these four genes was decreased in both the primary pancreatic cancer group and the metastatic pancreatic cancer group, and the latter was more significantly reduced. Pancreatic cancer metastasis is closely related to the activation of PPAR pathway, PI3K‐Akt pathway and ECM receptor interaction. SCG5, CRYBA2, CPE and CHGB genes are associated with the prognosis of pancreatic cancer, and their low expression suggests a poor prognosis.     

Suppression of lung cancer cell invasion and metastasis by connexin43 involves the secretion of follistatin-like 1 mediated via histone acetylation

Although connexin has been recognized as a tumor suppressor in many types of cancer, the underlying mechanisms are poorly understood. We have previously shown that transfection of connexin43 (Cx43) cDNA retarded the growth of a highly metastatic human pulmonary giant cell carcinoma cell line, PG, both in vitro and in vivo. Here, we further demonstrate that the metastasis and invasion, but not the migration, of PG cells are also inhibited following Cx43 transfection. The diminishment of metastasis and invasion is associated with down-regulation of genes including MMP-2, S100A, LAMA4, and HDAC10, as well as up-regulation of genes such as MTSS1 and FSTL1 as revealed by gene chip analysis. Interestingly, the suppression effects of Cx43 are related to secreted factor(s), which are blocked by FSTL1 antibody treatment in a dose-dependent manner. Furthermore, the FSTL1 promoter was shown to be associated with acetylated histones H3 and H4 upon Cx43 transfection. These data suggest that Cx43 inhibits the invasion and metastasis of PG cells by modulating the secretion of FSTL1, which is regulated by histone acetylation. Cx43 may act as a "histone deacetylase inhibitor" to modulate gene expression and subsequent cellular functions in PG cells.     

Newly identified tumor-associated role of human Sharpin

In order to discover previously unidentified cancer-associated genes, we analyzed genome-wide differences in gene expression between tumor biopsies and normal tissues. Among those differentially regulated genes, we identified Sharpin (Shank-associated RH domain-interacting protein) as a commonly up-regulated gene in multiple human cancer types. Although rat Sharpin is reported to interact with Shank1, a multidomain scaffold protein localized in postsynaptic densities, its exact roles are unknown. Whereas human Sharpin homologue was primarily localized in the cytosol of cultured cells, they were detected in both cytosol and nucleus of the cells from ovarian and liver cancer tissues using immunohistochemical staining. In addition, Chinese ovary hamster cells over-expressing Sharpin exhibited enhanced cancer-specific phenotypes in multiple in vitro tumor assays. Taken together, the results suggest that Sharpin is not an inert scaffold protein, but may play tumor-associated roles during cancer biogenesis.